Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown

Shares successful Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 aft Deutsche Bank pointed to a continued slowdown successful the oral mentation of the company's Wegovy weight-loss cause successful the US.

The slope published its play tracker of medicine information for Novo's GLP-1 franchise, the people of appetite-suppressing treatments that has driven the company's growth. The investigation draws connected IQVIA figures up to 26 June.

Deutsche Bank singled retired the nonaccomplishment of momentum successful the Wegovy pill arsenic the notable displacement this week.

The oral formulation had been seen arsenic a cardinal maturation driver, offering patients an alternate to play injections and a mode for Novo to broaden the market.

A weaker trajectory for the pill matters due to the fact that rivals are racing to bring their ain oral weight-loss treatments to market.

Extrapolating existent trends, adjacent including the regulator past period granting selling authorisation to Novo's oral tablet, the slope expects single-digit downside for the Wegovy pill implicit the 2026 fiscal year.

It sees double-digit downside for the injectable version, Wegovy SC, and for Rybelsus, Novo's older oral diabetes drug.

Ozempic was the 1 agleam spot, with the slope pencilling successful double-digit upside for the year.

Four-week rolling full prescriptions for injectable Wegovy were up 37% to 38%.

Ozempic prescriptions fell 12% to 13% connected the aforesaid basis.

Wegovy and Ozempic are some marque names for the aforesaid progressive ingredient, semaglutide, but Wegovy is specifically formulated for value management, portion Ozempic is licensed to dainty benignant 2 diabetes.

Deutsche Bank rates Novo 'hold', with a DKK290 terms people that sits beneath the existent stock price.

The tracker reflects the bank's ain speechmaking of the medicine information alternatively than figures published by the company.